Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 8(1): 2447, 2018 02 05.
Artigo em Inglês | MEDLINE | ID: mdl-29402960

RESUMO

Mucociliary clearance is a biomechanical mechanism of airway protection. It consists of the active transport along the bronchial tree of the mucus, a fluid propelled by the coordinated beating of a myriad of cilia on the epithelial surface of the respiratory tract. The physics of mucus transport is poorly understood because it involves complex phenomena such as long-range hydrodynamic interactions, active collective ciliary motion, and the complex rheology of mucus. We propose a quantitative physical analysis of the ciliary activity and mucus transport on a large panel of human bronchial cultures from control subjects, patients with asthma and chronic obstructive pulmonary disease obtained from endobronchial biopsies. Here we report on the existence of multiple ciliary domains with sizes ranging from the tens of a micron to the centimeter, where ciliary beats present a circular orientational order. These domains are associated with circular mucus flow patterns, whose size scales with the average cilia density. In these domains, we find that the radial increase of the ciliated cell density coupled with the increase in the orientational order of ciliary beats result in a net local force proportional to the mucus velocity. We propose a phenomenological physical model that supports our results.


Assuntos
Brônquios/ultraestrutura , Cílios/ultraestrutura , Depuração Mucociliar/fisiologia , Muco/fisiologia , Mucosa Respiratória/ultraestrutura , Asma/metabolismo , Asma/fisiopatologia , Fenômenos Biomecânicos , Brônquios/metabolismo , Brônquios/fisiopatologia , Broncoscopia , Estudos de Casos e Controles , Cílios/metabolismo , Cílios/patologia , Humanos , Hidrodinâmica , Modelos Biológicos , Doença Pulmonar Obstrutiva Crônica/metabolismo , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Mucosa Respiratória/metabolismo , Mucosa Respiratória/fisiopatologia , Reologia , Técnicas de Cultura de Tecidos
2.
Am J Respir Crit Care Med ; 188(6): 703-9, 2013 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-23947381

RESUMO

RATIONALE: Neutrophil serine proteases in cystic fibrosis (CF) lung secretions partially resist inhibition by natural and exogenous inhibitors, mostly because DNA impairs their control. Cationic polypeptides display the property of condensing DNA and retain antimicrobial properties. We hypothesized that DNA condensation by cationic polypeptides in CF sputum would result in a better control of CF inflammation and infection. OBJECTIVES: We examined whether poly-L-lysine would compact DNA in CF lung secretions and liquefy CF sputum, improve the control of extracellular proteases by exogenous inhibitors, and whether it displays antibacterial properties toward CF-associated bacteria. METHODS: We used fluorogenic methods to measure proteolytic activities and inhibition by protease inhibitors in whole sputum homogenates from patients with CF before and after treatment with poly-L-lysine. Antibacterial properties of poly-L-lysine were measured in bacterial cultures and in whole CF sputum. Poly-L-lysine toxicity was evaluated after aerosolization by histologic analysis, flow cytometry, and quantification of proinflammatory cytokines. MEASUREMENTS AND MAIN RESULTS: Poly-L-lysine compacts CF sputum DNA, generating a liquid phase that improves ciliary beating frequency at the lung epithelial surface, and allows the control of neutrophil elastase and cathepsin G by their natural inhibitors. It retains antimicrobial properties against Pseudomonas aeruginosa and Staphylococcus aureus at doses that induce no inflammation in the mouse lung after aerosol administration. CONCLUSIONS: Poly-L-lysine may be an alternative to dornase-α to liquefy sputum with added benefits because it helps natural inhibitors to better control the deleterious effects of extracellularly released neutrophil serine proteases and has the ability to kill bacteria in CF sputum.


Assuntos
Antibacterianos/farmacologia , Fibrose Cística/tratamento farmacológico , DNA/efeitos dos fármacos , Lisina/farmacologia , Peptídeo Hidrolases/efeitos dos fármacos , Escarro/efeitos dos fármacos , Adulto , Idoso , Animais , Catepsina G/efeitos dos fármacos , Catepsina G/metabolismo , Fibrose Cística/metabolismo , DNA/metabolismo , Modelos Animais de Doenças , Feminino , Citometria de Fluxo/métodos , Humanos , Elastase de Leucócito/efeitos dos fármacos , Elastase de Leucócito/metabolismo , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Masculino , Camundongos , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Peptídeo Hidrolases/metabolismo , Proteólise/efeitos dos fármacos , Pseudomonas aeruginosa/efeitos dos fármacos , Escarro/metabolismo , Staphylococcus aureus/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...